Valuation: Charles River Laboratories International, Inc.

Market Cap 1.11TCr 971.39Cr 892.71Cr 832.11Cr 1.58TCr 1,05800Cr 1.6TCr 11TCr 4.17TCr 52TCr 4.17TCr 4.08TCr 1,79200Cr P/E 2026 *
37.6x
P/E 2027 * 25.2x
Enterprise Value 1.29TCr 1.13TCr 1.04TCr 967.95Cr 1.84TCr 1,23100Cr 1.86TCr 12TCr 4.85TCr 60TCr 4.85TCr 4.75TCr 2,08500Cr EV / Sales 2026 *
3.36x
EV / Sales 2027 * 3.19x
Free-Float
97%
Yield 2026 *
-
Yield 2027 * -
02/07 Charles River Laboratories International Insider Sold Shares Worth $16,875,000, According to a Recent SEC Filing MT
01/07 Argus Raises Price Target on Charles River Laboratories International to $250 From $200, Maintains Buy Rating MT
18/06 Charles River Laboratories International, Inc. and Eli Lilly and Company Enter Collaboration to Optimize Ai/Ml Platform Through Nonclinical Testing Expertise CI
18/06 Rothschild & Co Redburn Adjusts Charles River Laboratories International PT to $241 From $230, Maintains Buy Rating MT
18/06 Charles River Laboratories Shares Rise After Morgan Stanley Upgrade MT
17/06 Morgan Stanley Upgrades Charles River Laboratories International to Overweight From Equal Weight, Adjusts PT to $220 From $185 MT
05/06 Charles River Laboratories Has Potential to Outperform in 2H 2026, RBC Says MT
03/06 Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 09:55 AM
03/06 Charles River Laboratories International, Inc. Presents at 46th Annual William Blair Growth Stock Conference, Jun-02-2026 10:00 AM
13/05 Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing MT
13/05 Charles River Laboratories and Medipost sign non-exclusive MoU to advance GMP testing solutions RE
13/05 Charles River Laboratories and MEDIPOST Co., Ltd. Sign Non-Exclusive MOU to Collaborate on GMP-Compliant Testing and Commercial and Marketing Efforts CI
12/05 Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors CI
1 day+0.70%
1 week+6.92%
Current month+1.72%
1 month+28.25%
3 months+32.66%
6 months+13.97%
Current year+15.65%
1 week 214.76
Extreme 214.76
236.62
1 month 178.92
Extreme 178.92
236.62
Current year 146.2
Extreme 146.195
236.62
1 year 144.26
Extreme 144.26
236.62
3 years 91.86
Extreme 91.8609
275
5 years 91.86
Extreme 91.8609
460.21
10 years 67.2
Extreme 67.2
460.21
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Date Insider Type Main position Quantity % Market Cap.
29/06Sell

Director

-75,000 0.1557%
05/06Don

Chief Executive Officer

-6,772 0.0141%
05/06Don

Director

-3,66,722 0.7613%
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%+6.92%+46.82%+10.55% 1.11TCr
+1.70%+7.41%+3.12%+8.46% 4.91TCr
+0.92%+3.93%+399.71%+605.33% 4.02TCr
+1.89%+8.32%+26.06%-6.35% 3.46TCr
+2.38%+6.35%+21.25%+64.58% 3.31TCr
+3.96%+10.67%+11.89%+38.86% 2.52TCr
+2.51%+5.27% - - 1.7TCr
+2.58%+5.79%+73.44%+133.27% 1.59TCr
+0.32%+0.58%+13.67%+19.09% 1.38TCr
-1.14%+1.88%+15.30%-28.79% 1.33TCr
Average +1.58%+6.17%+67.92%+93.89% 2.53TCr
Weighted average by Cap. +1.76%+6.37%+85.55%+126.04%

Financials

2026 *2027 *
Net sales 384.69Cr 336.29Cr 309.05Cr 288.07Cr 546.39Cr 37TCr 554.68Cr 3.71TCr 1.44TCr 18TCr 1.44TCr 1.41TCr 62TCr 392.41Cr 343.05Cr 315.26Cr 293.86Cr 557.36Cr 37TCr 565.82Cr 3.78TCr 1.47TCr 18TCr 1.47TCr 1.44TCr 63TCr
Net income 29Cr 25Cr 23Cr 21Cr 40Cr 2.71TCr 41Cr 275Cr 106.91Cr 1.33TCr 107.03Cr 104.73Cr 4.6TCr 42Cr 36Cr 34Cr 31Cr 59Cr 3.97TCr 60Cr 402.49Cr 156.47Cr 1.95TCr 156.64Cr 153.28Cr 6.73TCr
Net Debt 181.4Cr 158.58Cr 145.73Cr 135.84Cr 257.65Cr 17TCr 261.56Cr 1.75TCr 680.14Cr 8.49TCr 680.9Cr 666.28Cr 29TCr 138.82Cr 121.36Cr 111.53Cr 103.96Cr 197.18Cr 13TCr 200.17Cr 1.34TCr 520.49Cr 6.5TCr 521.08Cr 509.89Cr 22TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change Volume
02/26/02 $230.69 +0.70% 8,45,345
01/26/01 $229.09 +1.01% 10,86,091
30/26/30 $226.79 +0.54% 10,61,317
29/26/29 $225.57 +4.55% 10,91,785
26/26/26 $215.75 +1.43% 14,45,803
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
230.69USD
Average target price
215.33USD
Spread / Average Target
-6.66%

Quarterly revenue - Rate of surprise